Claims

1. Use of a compound of formula (I),



formula (I)

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment, prevention or alleviation of pain in a subject, wherein the compound is to be administered in an amount of 0.5 mg to 10 mg per individual dose.

2. The use according to claim 1, wherein the compound is exo-7-[(8-azabicyclo[3.2.1]octan-3-yl)oxy]-3-methoxy-chromen-2-one hydrochloride.

3. The use according to any one of the preceding claims, wherein the compound of formula I is to be administered in an amount per individual dose from 1 mg to 10 mg, such as from 1 mg to 10 mg per individual dose, such as from 3 to 10 mg per individual dose, such as about 5 mg per individual dose, such as about 10 mg per individual dose.

4. The use according to any one of the preceding claims, wherein the compound is to be administered orally in an amount per individual dose from 0.01 to 0.25 mg/kg, such as 0.01 mg/kg, such as 0.05 mg/kg, such as 0.1 mg/kg, such as 0.15 mg/kg, such as 0.2 mg/kg, such as 0.25 mg/kg.

5. The use according to any one of the preceding claims, wherein the compound is to be administered once daily, or more than once daily, such as 2 times a day, such as 3 times a day, such as 4 times a day.

6. The use according to any one of the preceding claims, wherein the pain is selected from the group consisting of: acute pain, chronic pain, mild pain, moderate or severe pain, postoperative pain, neuropathic pain, central neuropathic pain, pain related to diabetic neuropathy, to postherpetic neuralgia, to peripheral nerve injury, to phantom limb pain, to neurogenic inflammation, to fibromyalgia, to chronic regional pain syndrome, somatic pain, visceral pain or cutaneous pain, pain caused by inflammation or by infection, pain related to

arthritis, osteoarthritis, rheumatoid arthritis, neuronal hyperexcitability disorders, peripheral nerve hyperexcitability, back pain, cancer pain, dental pain, irritable bowel pain, irritable bowel syndrome, post-operative pain, post-mastectomy pain syndrome (PMPS), post-stroke pain, drug-induced neuropathy, complex regional pain syndrome (CRPS), sympathetically maintained pain (SMP), trigeminal neuralgia, myofacial pain, chronic headache, migraine, migraine-related disorders or tension-type headache.

7. The use according to any one of the preceding claims, wherein the pain is selected from the group consisting of:

(i) chronic or acute primary pain,
(ii) chronic or acute cancer related pain,
(iii) chronic or acute postsurgical pain,
(iv) chronic or acute post-traumatic pain,
(v) chronic or acute secondary musculoskeletal pain,
(vi) chronic or acute secondary visceral pain,
(vii) chronic or acute neuropathic pain, and
(viii) chronic or acute secondary headache or orofacial pain.

8. The use according to any one of the preceding claims, wherein the pain is neuropathic pain.

9. The use according to any one of the preceding claims, wherein the pain is trigeminal neuralgia.

10. The use according to any one of the preceding claims, wherein the pain is sexual pain disorder, such as vulvar pain, or pain associated with genitourinary syndrome of menopause (GSM), or pain associated with vaginal atrophy, vulvovaginal atrophy, urogenital atrophy, or atrophic vaginitis.

11. The use according to any one of the preceding claims, wherein the pain is vulvodynia or progressive vulvodynia.

12. The use according to any one of the preceding claims, wherein the subject is to be administered with a further therapeutic agent effective for the treatment of pain; such as wherein the further therapeutic agent is selected from the group consisting of: opioid receptor agonists, such as tramadol or tapentadol, methadone, nalbuphine, butorphanol, oxycodone, or morphine; non-steroidal anti-inflammatory drugs, such as COX-2 inhibitors, diclofenac, naproxen, ibuprofen, celecoxib, mefenamic acid, etoricoxib, or indomethacin; and an agent that is effective for the treatment of neuropathic pain, such as a further therapeutic agent selected from the group consisting of: gamma-amino butyric acid analogs, such as gabapentin, or pregabalin; capsaicinoids, such as capsaicin; dual serotonin-norephrine reuptake inhibitors, such as duloxetine; anticonvulsants, such as carbamazepine, or oxacarbazepine; tricyclic antidespressants, such as amitriptyline, or nortriptyline; transient receptor potential cation channel subfamily V member 1 (TRPV1) receptor modulators, such as a TRPV1 receptor agonist, or a TRPV1 receptor antagonist; and neurokinin receptor modulators, such as neurokinin receptor antagonists or neurokinin receptor agonists.

13. The use according to any one of the preceding claims, wherein the compound is capable of inducing a pain reduction in a subject of at least 5%, such as at least 10%, such as at least 15%, such as 20% pain reduction, such as 30%, such as 40%, such as 50%, such as 60%, such as 70%, or higher pain reduction in a subject.

14. The use according to any one of the preceding claims, wherein the administration of the compound is an oral administration.

15. The use according to any one of the preceding claims, wherein the compound is formulated in a pharmaceutical composition further comprising a pharmaceutically acceptable diluent, carrier and/or excipient; for example wherein the compound is formulated as a solid dosage form, such as a tablet, a capsule, a pill, granules, or a powder.